Somatic Symptom Disorders Workup
- Author: William R Yates, MD, MS; Chief Editor: Eduardo Dunayevich, MD more...
If indicated, specific studies used to rule out somatization due to general medical conditions include the following:
- Thyroid function studies - Thyroid stimulating hormone (TSH) at 0.4-10 mIU/L and thyroxine at 5.0-12.5 ng/dL
- Pheochromocytoma screen - Urine catecholamines, homovanillic acid (HVA) 2-12 mg per 24 hours, vanillylmandelic acid (VMA) 2-7 mg per 24 hours, metanephrines less than 1.6 mg per 24 hours, and norepinephrine plus epinephrine less than 100 mcg per 24 hours
- Urine drug screen - Including cannabis, amphetamine, hallucinogens, cocaine, opioids, benzodiazepines
- Blood studies - To screen for occult alcoholism
- Psychological testing - Minnesota Multiphasic Personality Inventory (MMPI) may provide insight into the likelihood of a somatic symptom disorder. (Negative MMPI studies should encourage further pursuit of a medical cause for the symptoms.)
Imaging studies are not routinely used in diagnosing the somatic symptom disorders. However, functional MRI may be of use in the diagnosis of some conditions such as unexplained visual loss. Imaging studies also may be helpful to rule out unexplained physical symptoms due to a medical disorder.
Avoid invasive diagnostic procedures and aggressive surgical assessment.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association. Fourth Edition. Washington, DC: American Psychiatric Association; 2000. Text Revision.
Atmaca M, Sirlier B, Yildirim H, Kayali A. Hippocampus and amygdalar volumes in patients with somatization disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15. 35(7):1699-703. [Medline].
van der Kruijs SJ, Bodde NM, Vaessen MJ, Lazeron RH, Vonck K, Boon P, et al. Functional connectivity of dissociation in patients with psychogenic non-epileptic seizures. J Neurol Neurosurg Psychiatry. 2012 Mar. 83(3):239-47. [Medline].
Baumeister H, Härter M. Prevalence of mental disorders based on general population surveys. Soc Psychiatry Psychiatr Epidemiol. 2007 Jul. 42(7):537-46. [Medline].
Baruffol E, Thilmany MC. Anxiety, depression, somatization and alcohol abuse. Prevalence rates in a general Belgian community sample. Acta Psychiatr Belg. 1993 May-Jun. 93(3):136-53. [Medline].
Chioqueta AP, Stiles TC. Suicide risk in patients with somatization disorder. Crisis. 2004. 25(1):3-7. [Medline].
Kendler KS, Aggen SH, Knudsen GP, Røysamb E, Neale MC, Reichborn-Kjennerud T. The structure of genetic and environmental risk factors for syndromal and subsyndromal common DSM-IV axis I and all axis II disorders. Am J Psychiatry. 2011 Jan. 168(1):29-39. [Medline]. [Full Text].
Maes M, Galecki P, Verkerk R, Rief W. Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity. Neuro Endocrinol Lett. 2011. 32(3):264-73. [Medline].
Katzer A, Oberfeld D, Hiller W, Gerlach AL, Witthöft M. Tactile perceptual processes and their relationship to somatoform disorders. J Abnorm Psychol. 2012 May. 121(2):530-43. [Medline].
Werring DJ, Weston L, Bullmore ET. Functional magnetic resonance imaging of the cerebral response to visual stimulation in medically unexplained visual loss. Psychol Med. 2004 May. 34(4):583-9. [Medline].
Martin A, Rauh E, Fichter M, Rief W. A one-session treatment for patients suffering from medically unexplained symptoms in primary care: a randomized clinical trial. Psychosomatics. 2007 Jul-Aug. 48(4):294-303. [Medline].
Smith GR Jr, Monson RA, Ray DC. Psychiatric consultation in somatization disorder. A randomized controlled study. N Engl J Med. 1986 May 29. 314(22):1407-13. [Medline].
Barsky AJ, Ahern DK. Cognitive behavior therapy for hypochondriasis: a randomized controlled trial. JAMA. 2004 Mar 24. 291(12):1464-70. [Medline].
Bleichhardt G, Timmer B, Rief W. Cognitive-behavioural therapy for patients with multiple somatoform symptoms--a randomised controlled trial in tertiary care. J Psychosom Res. 2004 Apr. 56(4):449-54. [Medline].
Beltman MW, Voshaar RC, Speckens AE. Cognitive-behavioural therapy for depression in people with a somatic disease: meta-analysis of randomised controlled trials. Br J Psychiatry. 2010 Jul. 197(1):11-9. [Medline].
Huang M, Luo B, Hu J, Wei N, Chen L, Wang S, et al. Combination of citalopram plus paliperidone is better than citalopram alone in the treatment of somatoform disorder: results of a 6-week randomized study. Int Clin Psychopharmacol. 2012 May. 27(3):151-8. [Medline].
Egloff N, Cámara RJ, von Känel R, Klingler N, Marti E, Ferrari ML. Hypersensitivity and hyperalgesia in somatoform pain disorders. Gen Hosp Psychiatry. 2014 May-Jun. 36(3):284-90. [Medline].
Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med. 2007 Dec. 69(9):881-8. [Medline].
Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jönsson B. The economic cost of brain disorders in Europe. Eur J Neurol. 2012 Jan. 19(1):155-62. [Medline].
Roca M, Gili M, Garcia-Garcia M, Salva J, Vives M, Garcia Campayo J, et al. Prevalence and comorbidity of common mental disorders in primary care. J Affect Disord. 2009 Apr 9. [Medline].
Sumathipala A, Siribaddana S, Abeysingha MR, De Silva P, Dewey M, Prince M, et al. Cognitive-behavioural therapy v. structured care for medically unexplained symptoms: randomised controlled trial. Br J Psychiatry. 2008 Jul. 193(1):51-9. [Medline].
van Ravesteijn H, Wittkampf K, Lucassen P, van de Lisdonk E, van den Hoogen H, van Weert H, et al. Detecting somatoform disorders in primary care with the PHQ-15. Ann Fam Med. 2009 May-Jun. 7(3):232-8. [Medline].